Multiple Hereditary Exostosis (MHE) is a rare genetic disorder characterized by the development of multiple Benign Bone Tumors (osteochondromas) that can lead to physical deformities, pain, and, in severe cases, restricted mobility. As awareness about MHE and other hereditary conditions increases, the need for effective diagnosis and therapeutic interventions has surged.
With advancements in genetic screening and diagnostics, early detection of MHE is becoming more feasible, which allows for timely intervention and improved patient outcomes. Genetic testing has become a vital tool in identifying carriers and at-risk individuals, enabling personalized treatment plans and targeted therapies. The demand for such diagnostic technologies is growing as more healthcare providers recognize the importance of early diagnosis in managing genetic disorders like MHE.
Furthermore, the rise in genetic counseling services plays a significant role in market growth. Families with a history of MHE or other genetic conditions are increasingly seeking guidance to understand the risks and implications of the disorder. This has fueled the need for specialized healthcare services, further driving the global MHE market.
For instance, in December 2019, according to an article published by National Institutes of Health, the prevalence of HME (Hereditary Multiple Exostoses) in Western populations is estimated to range between 0.4 to 1 per 50,000 individuals. However, among the Chamorro people of Guam, the prevalence is significantly higher, reaching 50 per 50,000. In Western countries, the incidence of this condition is reported to increase by 1.5% annually. This rising prevalence of genetic disorders, such as HME, highlights the growing need for effective treatments, which will drive the global multiple hereditary exostosis market as healthcare systems prioritize diagnosis and management of such conditions.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-multiple-hereditary-exostosis-market
Data Bridge Market Research analyzes that the Global Multiple Hereditary Exostosis Market is expected to reach USD 161.89 million by 2031 from USD 121.25 million in 2023 and is expected to grow at a CAGR of 3.7% in the forecast period of 2024 to 2031. Multiple Hereditary Exostosis (MHE) predominantly affects children, typically presenting symptoms during early childhood or adolescence. As the global pediatric population grows, there is an increased likelihood of more cases being diagnosed, which directly fuels the demand for early diagnosis and effective treatment options.
Key Findings of the Study
Growing Pediatric Population
Multiple Hereditary Exostosis (MHE) predominantly affects children, typically presenting symptoms during early childhood or adolescence. As the global pediatric population grows, there is an increased likelihood of more cases being diagnosed, which directly fuels the demand for early diagnosis and effective treatment options. MHE can cause bone deformities, restricted movement, and complications that significantly impact a child's growth and quality of life, making timely intervention essential.
The growing global pediatric population, combined with the fact that MHE primarily affects children, is a significant driver of the global MHE market. The increased focus on early diagnosis, specialized pediatric care, and treatment innovations is boosting demand for genetic screening and therapeutic interventions. As the pediatric population continues to expand, the global MHE market is expected to experience sustained growth in the foreseeable future.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Sessile and Pedunculated), Treatment (Surgery, Medication, and Others), Diagnosis (X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others), Site (Legs, Arms, Shoulders, Pelvis, Fingers, and Toes), Age Group (Pediatric and Adult), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Russia, Turkey, Switzerland, Belgium, Netherland, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, U.A.E., and Rest of Middle East and Africa
|
|
Market Players Covered
|
Bayer AG (Germany), Haleon Group of Companies (UK), BASF (Germany), Viatris Inc. (U.S.), Mallinckrodt (U.S.), AdvaCare Pharma (U.S.), Aurobindo Pharma (India), Taj Pharmaceutical Limited (India), Wellona Pharma (India), and ActizaPharma (India) among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Global multiple hereditary exostosis market is segmented into six notable segments based on type, treatment, diagnosis, site, age group, and end user.
- Based on type, the market is segmented into sessile and pedunculated
In 2024, the sessile segment is expected to dominate the global multiple hereditary exostosis market
In 2024, the sessile segment is expected to dominate the market with a market share of 54.72% due to the rising cases of sessile MHE.
- Based on treatment, the market is segmented into medications, surgery, and others
In 2024, the surgery segment is expected to dominate the global multiple hereditary exostosis market
In 2024, the surgery segment is expected to dominate the market with a market share of 54.26% due to the rising adoption of surgery for the treatment of MHE.
- Based on diagnosis, the market is segmented x-ray, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), genetic tests, and others. In 2024, the x-ray segment is expected to dominate the market with a market share of 38.85%
- Based on site, the market is segmented into legs, arms, shoulders, pelvis, fingers, and toes. In 2024, the legs segment is expected to dominate the market with a market share of 48.87%
- Based on age group, the market is segmented into pediatric and adult. In 2024, the pediatric segment is expected to dominate the market with a market share of 90.94%
- Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory centers, and others. In 2024, the hospitals is expected to dominate the market with a market share of 56.78%
Major Players
Data Bridge Market Research analyzes Bayer AG (Germany), Haleon Group of Companies (UK), BASF (Germany), Viatris Inc. (U.S.), Mallinckrodt (U.S) as the major players operating in the market.
Market Development
- In January 2023, Ipsen entered into acquisition of Albireo, enhancing its rare disease portfolio with Bylvay (odevixibat), the first approved treatment for progressive familial intrahepatic cholestasis. This strategic move aims to accelerate growth in rare pediatric liver diseases, bolstering Ipsen’s market presence and expanding treatment options for underserved patients
Regional Analysis
Geographically, the countries covered in the global multiple hereditary exostosis market report are the U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Russia, Turkey, Switzerland, Belgium, Netherland, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, U.A.E., and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global multiple hereditary exostosis market
North America is expected to dominate the market due to the several factors, primarily related to healthcare infrastructure, research and development, awareness, and access to advanced treatment options. North America, especially the United States, has a well-established and advanced healthcare system, allowing for better diagnosis, treatment, and management of rare diseases like multiple hereditary exostosis.
Asia-Pacific is the fastest growing region in the global multiple hereditary exostosis market
Asia-Pacific is fastest growing region in the global multiple hereditary exostosis market due increase in patient care and support systems.
For more detailed information about the global multiple hereditary exostosis market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-multiple-hereditary-exostosis-market
